A federal judge on Wednesday signed off on Pfizer Inc's $345 million settlement resolving claims by consumers who say they overpaid for the emergency allergy treatment EpiPen, and awarded plaintiffs' firms including Robbins Geller Rudman & Dowd and Keller Rohrback $115 million in fees.
EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers. August 24, 2016. REUTERS/Jim BourgViatris remains a defendant and faces trial in Januaryon Pfizer Inc's $345 million settlement resolving claims by consumers who say they overpaid for the emergency allergy treatment EpiPen, and awarded plaintiffs' firms including Robbins Geller Rudman & Dowd and Keller Rohrback $115 million in fees.
"We appreciate the court's careful analysis," said plaintiffs' attorney Lynn Sarko of Keller Rohrback.Pfizer said in a statement it was pleased with the deal's approval, and denied wrongdoing. Consumer lawsuits began piling up after Mylan in 2016 raised the price of a pair of EpiPens to $600 from $100 in 2008, amid an ongoing debate over high drug prices.
Mylan in 2017 agreed to pay $465 million to settle related claims by the U.S. government. Viatris remains a defendant in the class action and is scheduled to go to trial in January.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer agrees to let other companies make its Covid pill to allow broader global accessDrugmaker Pfizer Inc. has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental Covid-19 pill, a move that could make the treatment available to more than half of the world’s population.
Read more »
Pfizer agrees to let other companies make its COVID-19 pillDrugmaker Pfizer Inc. has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental COVID-19 pill, a move that could make the treatment available to more than half of the world’s population. In a statement issued Tuesday, Pfizer said it would grant a license for the antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the pill for use in 95 countries, making up about 53% of the world’s population. “It’s quite significant that we will be able to provide access to a drug that appears to be effective and has just been developed, to more than 4 billion people,” Esteban Burrone, head of policy at the Medicines Patent Pool, said.
Read more »
Pfizer signs license agreement to allow broader global access to its experimental Covid-19 antiviral pillPfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental Covid-19 pill.
Read more »
Pfizer agrees to let other companies make its COVID-19 pillLONDON (AP) — Drugmaker Pfizer Inc. has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental COVID-19 pill, a move that could make the treatment available to more than half of the world’s population.
Read more »